| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Statements of interest
The following authors have declared a statement of interest concerning papers published in volume 31 of the ERJ.
Statements of interest from previous volumes may be viewed here: volume 30; volume 29.
A
Back to Top
S.D. Aaron has received funds for speaking from GlaxoSmithKline and Boehringer Ingelheim. He has served on advisory boards for Boehringer Ingelheim and AstraZeneca. DOI: 10.1183/09031936.00098307
K.B. Adler has received research grants from AstraZeneca, Inc. and Sepracor, Inc. The author holds 150,000 founder’s shares in a start-up Biotech firm, BioMarck, Inc. K.B. Adler has also served on the scientific advisory board of Sepracor, Inc. and has received consulting fees of approximately US$5,000 in the last 2 years. DOI: 10.1183/09031936.00103307
P. Albert has received speaker fees and conference travel grants from GSK, AstraZeneca and Pfizer. DOI: 10.1183/09031936.00116707
S. Aldington. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
N. Ambrosino has received a fee for organising education and funds for a member of staff. A congress organised by N. Ambrosino has been sponsored by Vivisol. The institution of N. Ambrosino has received an educational grant from Vivisol. DOI: 10.1183/09031936.00143507
S.D. Anderson is the inventor of the patent that covers the use of mannitol for bronchial provocations and clearance of mucus. The patent is owned by the Sydney South West Area Health Service (SSWAHS) and licensed to Pharmaxis Ltd. The author may benefit from royalties in the future. S.D. Anderson owns shares in Pharmaxis Ltd that the author purchased herself, but does not own any options. In her capacity as an employee of the SSWAHS, the author consults for Pharmaxis Ltd and is on the Scientific Advisory Board of the company. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
W. Anderson is a full-time employee of the sponsor of the study GlaxoSmithKline, and holds stocks or shares in the organisation. He has acted as an expert witness on the subject of his study, review. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
L. Annemans. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
B
Back to Top
T.R. Bai has received fees for speaking, funds for research and fees for consulting. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
S. Baldassarre. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
S. Baraldo. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
P.J. Barnes has received funding for lectures and research from AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Boehringer Ingelheim and Nycomed, all of whom market drugs for respiratory diseases. DOI: 10.1183/09031936.00138707
E.D. Bateman has served on or currently serves on the advisory board for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyowa Hakko, Merck, Novartis, Nycomed, Pfizer and Sanofi-Aventis. The author has also received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Pfizer. His institution has received funding for research from Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Kyowa Hakko, Lilly, Merck, Novartis, Nycomed, Pfizer, Sanofi-Aventis and Schering Plough. DOI: 10.1183/09031936.00138707
E. Bazzan. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
R. Beasley. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
B. Beck-Schimmer has received a research grant from Abbott AG, Baar, Switzerland (US$30,000). The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
L. Beckert. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
J. Behr. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
K. Blondeau. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
S. Blumenthal. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
H.M. Boezen has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
A. Boonstra has acted as an expert witness on the subject of the study featured in the April 2008 issue of the European Respiratory Journal. He has received a consulting fee from Pfizer. DOI: 10.1183/09031936.00114207
C. Booy. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
C. Borland. British American Tobacco Ltd loaned Prof. Tim Higenbottam and Dr Colin Borland the original chemiluminescent nitric oxide analyser which was used for TLNO measurements in 1982–1985. DOI: 10.1183/09031936.00025108
L-P. Boulet is on the Advisory Boards of: AstraZeneca, Altana, GlaxoSmithKline, Merk Frosst and Novartis. He has received lecture fees from: 3M, AstraZeneca, Altana, GlaxoSmithKline, Merk Frosst and Novartis. He has received sponsorship for investigator-generated research from: AstraZeneca, GSK, Merck Frosst, Schering. Research funding for participating in multicentre studies has been given by: 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlasxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen, Wyeth. He has also received support for the production of educational materials from: AstraZeneca, GlaxoSmithKline and Merck Frosst. L-P. Boulet is an Adviser for the Conseil du Médicament du Québec and a member of the Quebec Workmen Compensation Board Respiratory Committee. He is also Chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee and co-leader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence. He currently holds the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI:10.1183/09031936.00104007
J. Bousquet has received funds for research and for consulting. He acted as an expert witness on the subject of the Global Guidelines presented. J. Bousquet has served on or currently serves on advisory boards for Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer, Stallergènes, Schering Plough, UCB and Uriach, and has received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Schering Plough, Stallergènes, UCB and Uriach. His institution has received funding for research from Almirall, Altana, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, Novartis, Nycomed, Schering Plough and Stallergènes. DOI: 10.1183/09031936.00138707
S. Bowler has received fees for consultation and or speaking from GSK, AstraZeneca, Boehringer Ingelheim and Altana Nycomed. DOI: 10.1183/09031936.00053107
P.H. Brekke’s travel to the ATS congress was funded by GlaxoSmithKline. DOI: 10.1183/09031936.00015807
C. Brouillard. The author’s study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
R.A. Brown. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
G. Brusselle. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
G. Buesching. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
J. Buffels. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
R. Buhl. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
D. Burkhart is an employee of Boehringer Ingelheim (Ridgefield, CT, USA). The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
A. Bush has received expenses to travel to the ATS and ERS Congresses from GSK, AstraZeneca, MSD, Actelion and Altana. The author has also received fees for chairing (n=1) and speaking (n=1) at Evening Symposia at ERS, and he has received fees for lecturing and chairing meetings from GSK, AstraZeneca, MSD and Chiron (no single fee exceeding €2,000). In no case has he used, nor been asked to use, material provided by the sponsor. His department has benefited from travel grants for research fellows from Chiron and GSK, and received research grants, in all cases administered through the Royal Brompton Hospital Research Dept, from Pharmaxis Australia (support of a research fellow), Chiron and MSD. The Institutions that employ him (Royal Brompton Hospital, Imperial College) benefit from substantial pharmaceutical funding from multiple companies, declared in their own conflict of interest statements. DOI: 10.1183/09031936.00172207
C
Back to Top
P.M.A Calverley has sat on advisory boards for GSK, AstraZeneca, Pfizer, Roche, Altana and Novartis as part of clinical trials supervision and study development. He has spoken at meetings supported by GSK, AstraZeneca, Boehringer Ingelheim, Altana and British Oxygen. His department has received research funding from GSK, Altana, BOC and Chiesi. DOI: 10.1183/09031936.00116707
F. Capron has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
C. Cassino was an employee of Boehringer Ingelheim (Ridgefield, CT, USA) at the time the study was conducted. The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
M.G. Castel-Branco. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207.
B.R. Celli is a consultant and member of a speakers’ bureau for Boehringer-Ingelheim and Pfizer, from whom he has received research grants. B.R. Celli has been on the advisory board of GlaxoSmithKline, Boehringer-Ingelheim, Dey Pharmaceutical, Sepracor, Altana, Almirall, AstraZeneca. The division he heads has grants from Boehringer-Ingelheim and GlaxoSmithKline. He has spoken for Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca and Almirall. The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
E.S. Chauliac. The Swiss Society of Paediatrics who provided funding for the author’s study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
A.D. Chew. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
G.W. Clarke. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
C. Compton is an employee of Pfizer Ltd. DOI: 10.1183/09031936.00033208.
J.E. Coote is employed by GlaxoSmithKline and holds a small number of their shares. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
G. Corvasce is a former employee of Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
U. Costabel. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
B. Cox. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
H.O. Coxson has received fees for speaking, funds for research, funds for a member of staff and fees for consulting. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
C. Crim is an employee and shareholder of GlaxoSmithKline, the sponsor of ECLIPSE. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D
Back to Top
C.W.H. Davies has been reimbursed for attending a working party group organised and paid for by LEO, the manufacturer of Innohep (tinzaparin), and also for presenting the study to employees of LEO. DOI: 10.1183/09031936.00156407
D.E. Davies is a co-founder and consultant of Synairgen, which has a programme involving a growth factor that shows some properties of EGF. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
E. Daviskas is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author may benefit from royalties in the future, owns shares in Pharmaxis Ltd that were purchased by the author herself, but does not own any options, and in her capacity as an employee of the SSWAHS, consults for Pharmaxis. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
F. Dawber is an employee and shareholder of GlaxoSmithKline, who is sponsoring ECLIPSE. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
L. De Bolle. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
Y.P. de Visser. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
M. Decramer has received fees for speaking and consulting from Boehringer and Pfizer. He has also receivced funds for research from AstraZeneca. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
M. Decramer is a consultant and member of a speakers’ bureau for Boehringer Ingelheim and Pfizer. The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
L. Delgado. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207.
M. Demedts has received consulting fees from Zambon, Wyeth and Roche, and lecture fees from GlaxoSmithKline, AstraZeneca and Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
J.C. Denyer is employed by GlaxoSmithKline and owns a small number of shares in GlaxoSmithKline. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
E. Derom received US$1,950 in 2002, US$2,280 in 2003 and US$2,495 in 2004 for serving on an advisory board for GlaxoSmithKline. The author received US$106,930 for the period 2003–2005 from Altana Pharma, US$5,890 for the period 2003–2005 from GlaxoSmithKline, US$100,280 in 2004 from SGS-Biopharma and $188,900 for the period 2003–2007 from Novartis, all as research grants for participating in clinical trials. The author has also received a grant from AstraZeneca to allow him to attend the ATS 2004, from Altana Pharma to attend the ERS 2005 Congress, and from AstraZeneca to attend the ERS 2006 Congress. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
R. Djukanović is a co-founder and consultant of Synairgen, which has a programme involving a growth factor that shows some properties of EGF. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
U. Domanski. The author’s study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
L.J. Dupont. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
L.J. Dupont is a senior research fellow of the FWO Vlaanderen – Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
J. Dupuis has received lecturer honorariums from Actelion Pharmaceuticals and Pfizer. He is also a member of scientific advisory boards for Actelion Pharmaceuticals and Encysive. DOI: 10.1183/09031936.00078207
E
Back to Top
S. Eberl is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
L. Edwards has been employed by an organisation that may gain or lose financially from the results of her study. She holds stocks or shares in an organisation that may gain or lose financially from the results of the study. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
R. Ellis. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
P. Ernst has received speaker fees and/or has served on advisory boards for Altana, AstraZeneca, GlaxoSmithKline and Merck Frosst, Canada. He is also the recipient of a CDN$150,000 research grant from GlaxoSmithKline. DOI: 10.1183/09031936.00098307
F
Back to Top
L.M. Fabbri has received funds for research, consulting fees, lecture fees and travel expense reimbursements for attending symposiums/meetings from Chiesi Farmaceutici, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKine, Pfizer, Roche, Altana, Novartis, Schering Pough and Menarini. DOI: 10.1183/09031936.00114307
L.M. Fabbri. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
J.M. Fitzgerald has received fees for speaking, for organising education, funds for research, funds for a member of staff and fees for consulting. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
M. FitzGerald has received fees for consulting on advisory boards and participated in speakers’ bureaus for a number of pharmaceutical companies, which market asthma drugs. These include: AstraZeneca, Nycomed, GSK, Merck and Novartis. He has participated on scientific advisory boards to biotechnology companies, including Inflazyme, Topigen and OSIS. In addition, he has received research funds, paid into academic research accounts at UBC for the companies listed above, as well as Skye Pharma, Wyeth and Genentech. DOI: 10.1183/09031936.00138707
C.D.R. Flower has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
K-J. Franke. The author’s study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
M. Frey. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
G
Back to Top
N. Geudens. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
P. Gibson and his institution have received honoraria for educational activities organised by AstraZeneca, GlaxoSmithKline and Novartis. His institution has received funding for research from GlaxoSmithKline, Novartis and Pharmaxis. DOI: 10.1183/09031936.00138707
M.M.E. Gosman. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
C. Grasemann. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
H. Grasemann. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
H
Back to Top
T. Haahtela. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
G. Hagan has been employed by an organisation that may gain or lose financially from the results of the study. He holds stocks or shares in an organisation that may gain or lose financially from the results of the study. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
A. Hansell. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
M. Harwood. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
P.S. Hiemstra has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
T. Higenbottam is an employee of AstraZeneca Ltd. DOI: 10.1183/09031936.00033208
J.A. Hirota. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
M.M. Hoeper has received fees for speaking at conferences and/or consultations from Actelion Pharmaceuticals, Encysive, GlaxoSmithKline, Pfizer, United Therapuetics and Bayer-Schering. DOI: 10.1183/09031936.00134407
M.M. Hoeper has received lecturer honoraria from Actelion Pharmaceuticals, Schering, Pfizer and Encysive. He is also a member of scientific advisory boards for Actelion Pharmaceuticals, Pfizer, GSK and Encysive. DOI: 10.1183/09031936.00078207
J.C. Hogg’s laboratory has, in the latter quarter of the last century, received support in the form of grants from the Canadian Tobacco Manufactures Council. This occurred both while J.C. Hogg was at McGill University in Montreal and for approximately 5 years after the author moved to Vancouver in 1977. The author also participated in a trial of the Eclipse cigarette, a “smokeless” product developed for harm reduction because it heated the tobacco rather than burned it. Between approximately 1996 and 2000 the author and colleagues tested the hypothesis that this product would either prevent and/or reverse the elevation in blood leukocyte count that smokers experience because particulate count in the smoke generated by this product is markedly reduced. It was found that it did not but the author was not able to publish this result because the major respiratory journals developed a policy against publishing tobacco-sponsored research about the time that the work was finished. To the best of the author’s recollection this study was complete in the year 2000 and he has received no funding from the tobacco industry since that time. DOI: 10.1183/09031936.00026208
Z. Hong is supported by an Actelion Young Investigators Award. DOI: 10.1183/09031936.00160407
S.S. Hurd received reimbursement for speaking at a symposium and fees for speaking. The author also received travel reimbursement from the Asian Pacific Society for Respirology for speaking in an educational seminar during their national meeting in 2006. DOI: 10.1183/09031936.00138707
M.J. Hurle is an employee of GlaxoSmithKline and as a part of his remuneration package holds a small number of shares in that company. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
I
Back to Top
M.D. Inman. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
J
Back to Top
T. Jacinto. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
L.J. Janssen. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
K
Back to Top
A. Kaplan has received speaking fees from the following companies: AstraZeneca, GlaxoSmithKline, Altana, Boehringer Ingelheim, Pfizer, Purdue, Ortho Janssen and Merck Frosst. The author has been on the advisory boards for Boehringer Ingelheim, Altana, AstraZeneca, Janssen Ortho, Merck Frosst, and Purdue. A. Kaplan has received funding for travel to report on proceedings of the ERS by AstraZeneca. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
S. Kesten is an employee of Boehringer Ingelheim (Ingelheim, Germany). The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
K. Knobil is employed by GSK and holds stocks or shares in GSK. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
M. Kraft has: received research funding from Genentech and GSK; participated as a consultant for GSK, Merck and Genentech; and received honoraria as a speaker for GSK, Merck, Genentech and Novartis. The author has also organised research activities for GSK. DOI: 10.1183/09031936.00103307
C.E. Kuehni. The Swiss Society of Paediatrics who provided funding for the author’s study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
L
Back to Top
Y. Lacasse. The author’s study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
E.H. Laghmani. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
E. Lammers. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
C. Lange has received speaker’s honoraria at symposia sponsored by Oxford Immunotec (manufacturer of T-SPOT.TB) and has served as a scientific advisor for Oxford Immunotec. DOI: 10.1183/09031936.00083707
I. Lankhorst has received consulting fees from Zambon and was formerly employed by Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
T.S. Lapperre. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
L.C. Lau. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
F. Laurent has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
M. Laviolette participated or participates in clinical trials for Altana, AstraZeneca, Boerinhger-Ingelheim, GlaxoSmithKline, Bayer, Merck, Asthmatx and Topigen. For the Asthmatx trials, M. Laviolette’s institution, the Laval Hospital, received $182,000 in 2004, $115,000 in 2005, $151,000 in 2006 and $169,000 in 2007 (to date) for reimbursement for expenses related to clinical trials of bronchial thermoplasty. M. Laviolette gave lecture’s sponsored by Altana, AstraZenenca, 3M, GlaxoSmithKline, Merck and Asthmatx. M. Laviolette received a medical research grant ($50,000) from Merck-Frosst in 2004 for a project that was published in JACI (2006; 118: 113–119). The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
C.L. Ledbetter. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
J.S-M. Lee has been employed by an organisation that may in any way gain or lose financially from the results of the study. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
M.L. Levy has received in the past 5 years reimbursement for attending a symposium, fees for speaking, fees for organising education and consulting, and funds for research. He has accepted sponsorship from the following for attending conferences: GlaxoSmithKline, AstraZeneca, Trinity-Cheisi, Merck Sharpe and Dohme, Merck, Altana Pharma, Novartis, Meda Pharmaceuticals, 3M Pharmaceuticals, Schering Plough. He has accepted lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Alk-Abello. M.L. Levy has also been on advisory boards or provided consultancy for Schering Plough, Merck Sharp and Dohme, Trinity-Cheisi, Altana Pharma, Ranbaxy, AstraZeneca, 3M Pharmaceuticals and Novartis. DOI: 10.1183/09031936.00157507
G. Liistro. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
D. Liu is or has been an employee of Boehringer Ingelheim. The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
D.A. Lomas has received fees for speaking, funds for research and fees for consulting. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
C. Lopes. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
M
Back to Top
W. MacNee has received research grants to support work carried out in the author’s laboratory from Pfizer, GlaxoSmithKline, Hoffmann La Roche, Telacris and Unilever. W. MacNee serves on an advisory board and expert panel for GlaxoSmithKline and SMB Pharmaceuticals. The author has received honoraria from GlaxoSmithKline and AstraZeneca for participating as a speaker in scientific meetings and travel to various meetings was funded by AstraZeneca, Zambon, Boehringer Ingelheim and GSK. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
P. Maestrelli. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
F. Maltais received fees for speaking at conferences sponsored by Boehringer Ingelheim, Pfizer and GlaxoSmithKline. He served on an advisory board for GlaxoSmithKline and Altana Pharma. He received research grants for participating in multicentre trials sponsored by GlaxoSmithKline, Boehringer Ingelheim, Altana Pharma and Merck. He received unrestricted researchs grant from Boehringer Ingelheim and GlaxoSmithKline. He has been reimbursed by AstraZeneca and Boehringer Ingelheim to attend two conferences. The author’s study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
D.M. Mannino has received research funding from GlaxoSmithKline, Pfizer and Novartis and has served as a consultant or speaker for GlaxoSmithKline, Pfizer, Boerhringer-Ingelheim, Astra-Zeneca, Dey and Sepracor. DOI: 10.1183/09031936.00017008
T.K. Marras has received an educational grant from Abbott, and speakers fees from Abbott and Bayer. DOI: 10.1183/09031936.00109007
S.A. Marsico. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
F.J. Martinez has received lecture honoraria from Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received reimbursement for attending advisory boards for Pfizer, Boehringer Ingelheim and GlaxoSmithKline. F.J. Martinez has received consultant fees from ALTANA Pharma, and received honoraria for organising education on behalf of Boehringer Ingelheim and Pfizer. Travel to the ERS Congress was funded by Pfizer. DOI: 01.1183/09031936.00099307
R. Maselli. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
E. Mehuys. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
V. Mertens. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
A. Michils. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
J. Milot has received a research fund from GlaxoSmithKline. The author’s study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
A. Moreira. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
R.D. Murdoch is an employee of GlaxoSmithKline, the sponsor of this research and holds stocks and shares. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
N
Back to Top
S.B. Neff. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
T.A. Neff. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
K. Nieuwland. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
A.G. Nicholson has received consulting fees from Zambon and lecture fees from AstraZeneca. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
G. Nilius. The author’s study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
O
Back to Top
P. O’Byrne received fees for speaking from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma. The author has also received funds: for research from Altana, AstraZeneca, Biolipox, Boehringer Ingelheim, GlaxoSmithKline, IVAX, Medimmune, Merck, Pfizer, Topigen and Wyeth; and for consulting from AstraZeneca, Biolipox, GlaxoSmithKline, Nycomed, Resistentia and Topigen. P. O’Byrne has received consulting fees from AstraZeneca, Biolipox, GlaxoSmithKline, Nycomed, Resistentia and Topigen, and honoraria for speaking from AstraZeneca, Chiesi, GlaxoSmithKline, Nycomed and Ono Pharma. In addition, he has received grants-in-aid from AstraZeneca, Biolipox, Boehringer Ingelheim, GlaxoSmithKline, IVAX, Medimmune, Merck, Pfizer, Topigen and Wyeth. DOI: 10.1183/09031936.00138707
B.J. O’Connor. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
K. Ohta has: served on or currently serves on advisory boards for Abbott/Maruho, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Tanabe Mitsubishi and Taisho; and received honoraria for scientific lectures organised by AstraZeneca, GlaxoSmithKline, Merck, Ono, Schering-Plough and Teijin. K. Ohta’s institution has received funding for research from AstraZeneca, GlaxoSmithKline and Otsuka. DOI: 10.1183/09031936.00138707
T. Omland has received: speaker’s honoraria from Roche Diagnostics, Bayer Diagnostics and Abbott Laboratories; consultancy honoraria from Roche Diagnostics; and research support from Roche Diagnostics and Abbott Laboratories, manufacturers of assays for troponin. DOI: 10.1183/09031936.00015807
P
Back to Top
C.P. Page is a member of the scientific advisory board for Endacea, Research Triangle Park, NC, USA, which is developing adenosine A1 receptor antagonists for the treatment of lung diseases. He holds stocks or shares. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
C. Palmares. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
J. Papassotiriou is an employee of BRAHMS AG, the manufacturer of the assay for procalcitonin. DOI: 10.1183/09031936.00054507
A. Papi. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
S.E. Pedersen has served on advisory boards for GlaxoSmithKline, AstraZeneca and Nycomed, and has received honoraria for educational activities organised by these three companies. His institution has received funding for research from AstraZeneca, GlaxoSmithKline, Merck and Nycomed. DOI: 10.1183/09031936.00138707
G. Pelaia. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
V. Pepin. The author’s study was supported by an unrestricted educational grant from GlaxoSmithKline (Canada) who provided the salmeterol and the placebo used in the study. The sponsor (GSK) was not involved in the study design, data collection, analysis and interpretation. The sponsor had the opportunity to read and comment on the manuscript with no obligation for the authors to incorporate any suggestion into the final version. DOI: 10.1183/09031936.00119007
W. Phanprasit has received consulting fees for conducting air monitoring in the milk powder factory described in the manuscript. DOI: 10.1183/09031936.00106407
E. Pizzichini has served on or currently serves on advisory boards for AstraZeneca, GlaxoSmithKline and Nycomed, and has received honoraria for educational activities organised by Altana/Nycomed, AstraZeneca and GlaxoSmithKline. DOI: 10.1183/09031936.00138707
A. Pritchard. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
M. Puhan. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
Q
Back to Top
R
Back to Top
K.F. Rabe reports having consulted, participated in advisory board meetings for and received lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Pfizer, Novartis, Altana Pharma, Merck Sharp & Dohme and GlaxoSmithKline. K.F. Rabe holds no stock or other equities in any pharmaceutical company. Between 2001–2006, the Dept of Pulmonology, of which the author is head, received grants from Altana Pharma, Novartis, Bayer, AstraZeneca, Pfizer, Merck Sharp & Dohme, Exhale Therapeutics, Boehringer Ingelheim, Roche and GlaxoSmithKline. DOI: 10.1183/09031936.00114307
F. Ratjen has received a fee for speaking at a symposium supported by Pharmacia. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
J.P. Remon. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
T. Renda. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
S.I. Rennard. In the last five years, S.I. Rennard has received financial support for speaking, consulting and/or to support research from Adams, Almirall, Altana, Array Biopharma, Astellas, AstraZeneca, Aventis, Bend Pharmaceuticals, Boehringer Ingelheim, Biolipos, Centocor, Critical Therapeutics, Dey Laboratories, GlaxoSmithKline, ICOS, Inspire Pharmaceuticals, Intermune, Johnson & Johnson, Lorillard, Merck, Nabi, Novartis, Ono, Otsuka, Parengenix, Pfizer, RJ Reynolds, Roche, Sankyo, Sanofi, Schering-Plough, Scios, Talecris and Wyeth. S.I. Rennard has also received fees for organising education. S.I. Rennard has in the past acted as a consultant to, and received grants from, the tobacco industry; these relationships ceased before January 1, 2008. DOI: 01.1183/09031936.00099307
E. Reutershahn. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
L. Reyes. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
G. Robinson. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
B. Roth Z’graggen. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
K-H. Ruhle has received research funding from Fisher & Paykel Healthcare, Heinen und Löwenstein, ResMed und Weinmann. This funding has gone into department funds. The author’s study was supported by a grant from Fisher & Paykel Healthcare Germany GmbH & Co. KG, 73636 Welzheim, Germany. DOI: 10.1183/09031936.00161806
P. Rytilä. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
P. Rytilä. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
S
Back to Top
M. Saetta. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
M. Sardina is a current employee of Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
T.J. Savage is employed by GlaxoSmithKline and holds a small number of their shares. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
T. Schermer has received reimbursement from GlaxoSmithKline and Boehringer Ingelheim for travelling to scientific conferences in the respiratory field (ERS and IPCRG). He has also received compensation for serving on an advisory board for AstraZeneca. The author's institute has received unrestricted educational grants from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
E.R. Schmid has received a research grant from Abbott AG, Baar, Switzerland (US$30,000). The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
D. Schnabel has received grant support from Pfizer, and has been invited as a symposium speaker. He has participated in multi-site clinical studies for Pfizer. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
C. Schudt was fully employed by Altana Research and development. DOI: 10.1183/09031936.00002007
H.J. Schünemann received no personal payments from for-profit organisations. In the past 5 years, he has received research grants, fees and/or honoraria that were deposited into research accounts from the American Thoracic Society (fees), AstraZeneca (research grant, honoraria), Amgen (research grant), Chiesi Foundation (honorarium), Lily (honorarium), Pfizer (research grant, honorarium), Roche (honorarium) and UnitedBioSource (honorarium) for development or consulting regarding quality-of-life instruments for chronic respiratory diseases or as lecture fees related to the methodology of evidence-based practice guideline development and/or research methodology. McMaster University and the CLARITY Research Group at McMaster University have received licensing fees for use of the Chronic Respiratory Questionnaire. H.J. Schünemann is Documents Editor for the American Thoracic Society. Other institutions or organisations that the author is affiliated with may receive funding from for-profit sponsors that are supporting infrastructure and research that may serve the author’s work. DOI: 10.1183/09031936.00163107
H.J. Schünemann. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
M.R. Sears has received research grants, consulting fees and speaker fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed (Altana), MerckFrosst Canada, Merck Sharp Dohme, Novartis and Schering-Plough and holds a Chair in Respiratory Epidemiology jointly endowed by AstraZeneca and McMaster University. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
W. Seeger has been reimbursed for participation in the ATS congress in 2004 by Altana Pharma AG and for participation in the Ventavis® Launch Symposium (Madeira) in 2003 by Schering AG. He received a fee for speaking from Schering AG for taking part in an Expert Round Table in Pulmonary Hypertension; from Schering AG for taking part in the Ventavis® Launch Symposium; from Pfizer AG for taking part in the 110. Annual Meeting of the German Society of Internal Medicine. He received funds for research for clinical studies funded by Altana Pharma AG, Actelion, Schering AG, Myogen Inc., Lung Rx. He received a fee for organising education for Graduate College financially supported by Altana Pharma AG. He received fees for consulting from Altana Pharma AG, Lung RX, Schering AG. Funding received in 2004: Schering Deutschland GmbH 12,000.00 Euro, Altana Pharma AG 40,000.00 Euro, Altana Pharma AG 12,811.00 Euro, Myogen Inc. Westminster 68,683.15 Euro, Lung Rx 351,368.23 Euro, Lung Rx $120,000.00, Altana Pharma AG 450,000.00 Euro. Funding received in 2005: Lung Rx $120,000.00, Encysive 77,414.23 Euro, Schering AG 5,000.00 Euro, Schering Deutschland GmbH 10,000.00 Euro, Altana Pharma AG 60,000.00 Euro, Altana Pharma AG 12,811.00 Euro, Schering Deutschland 40,000.00 Euro, Myogen Inc. Westminster 258,349.49 Euro, Altana Pharma AG 225,000.00 Euro. Funding received in 2006: Myogen Inc. Westminster/Gilead $120,000.00, Altana Pharma AG 12,811.00 Euro, Lung Rx $120,000.00, Schering AG 5,000.00 Euro. Funding received in 2007: Lung Rx $60,000.00, Schering AG 5,000.00 Euro, Gilead Colorado $34,125.00. DOI: 10/1183/09031936.00109407
G. Seumois. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
D. Sifrim. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
J.A. Silva. The author’s study was partly supported by an unrestricted grant from Laboratórios BIAL. DOI: 10.1183/09031936.00175207
M. Silverman. The Swiss Society of Paediatrics who provided funding for the author’s study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
E.K. Silverman has received: honorarium for a talk on COPD genetics in 2006, and grant support and consulting fees from GlaxoSmithKline for two studies of COPD genetics; honorarium from Wyeth for a talk on COPD genetics in 2004; honorarium from Bayer for a symposium at the ERS Meeting in 2005; honorarium from AstraZeneca for a talk at the Lund Symposium in 2007. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D.E. Simcock has received travel awards by the American Thoracic Society and the British Lung Foundation to attend international respiratory conferences. The author’s study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
N. Smiljanic-Georgijev was an employee of AstraZeneca and holds stocks or shares in an organisation that may in any way gain or lose financially from the results of the study. The author’s study was designed by AstraZeneca in collaboration with the authors, who have full access to all data generated in the study. The author’s study was funded by AstraZeneca Canada Inc. C. Macpherson provided editing assistance on the manuscript, which was funded by AstraZeneca. DOI: 10.1183/09031936.00104007
S. Smith has received funds for research. DOI: 10.1183/09031936.00053107
J.B. Snoeck-Stroband. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
J.B. Soriano received reimbursements for attending symposia, fees for speaking and fees for consulting. He was an employee of GlaxoSmithKline R&D up to 2005. DOI: 10.1183/09031936.00084507
D.R. Spahn. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
A. Spaar. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
D. Spina has received a grant to study adenosine receptor expression in the airways. This funding covered the cost of consumables and salary for a postdoctoral fellow to undertake the work presented in this manuscript. The study was funded by a grant from GlaxoSmithKline, Stevenage, UK. DOI: 10.1183/09031936.00003707
J.K. Sont has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
P.J. Sterk has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
M. Steurer. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
R.A. Stockley has had unrestricted research funding from Talecris and AstraZeneca. He has provided consultancy for AstraZeneca, GSK, Boehringer, Schering Plough and Talecris. He has lectured for GSK and has been supported for attendance to ATS and ERS by Talecris and Boehringer. OI: 10.1183/09031936.00081707
M-P.F. Strippoli. The Swiss Society of Paediatrics who provided funding for the author’s study was awarded a GlaxoSmithKline Scholarship for Paediatric Pulmonary in 2001. DOI 10.1183/09031936.00088407
S. Suissa has: participated in advisory board meetings (Boehringer Ingelheim, Pfizer, GlaxoSmithKline); given lectures (Boehringer Ingelheim, Pfizer); and received research grants from AstraZeneca. DOI: 10.1183/09031936.00098307
S.D. Sullivan has served on or currently serves on advisory boards for AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis and Schering Plough, and has received honoraria for educational activities organised by AstraZeneca, Novartis and Genentech. DOI: 10.1183/09031936.00138707
P. Supply has received fees for consulting and is a consultant of Genoscreen. DOI: 10.1183/09031936.00053307
T
Back to Top
R. Tal-Singer is an employee and shareholder of GlaxoSmithKline who sponsored the ECLIPSE study. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
D.P. Tashkin is a consultant and member of a speakers’ bureau for Boehringer Ingelheim and Pfizer, from whom he has received research grants. D.P. Tashkin has also received: fees for speaking from Boehringer-Ingelheim and Pfizer; a fee for organising education from a medical education company that received funding from Boehringer-Ingelheim and Pfizer; consulting fees from Boehringer-Ingelheim. The author’s study was supported by Boehringer Ingelheim and Pfizer. T. Keyser (Boehringer Ingelheim) provided editorial support in the preparation of the manuscript. DOI: 10.1183/09031936.00129607
N.H.T. ten Hacken has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
M. Thomeer has received consulting fees from Zambon and InterMune, and lecture fees from Zambon, InterMune, AstraZeneca and GlaxoSmithKline. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
W. Timens has received a grant from GlaxoSmithKline (UK and the Netherlands) as part of the GLUCOLD study. The present study was supported by GlaxoSmithKline, the Netherlands. DOI: 10.1183/09031936.00137006
A. Torres was supported by CIBER of Enfermedades Respiratorias (CB06/060028). DOI: 10.1183/09031936.00073807
G. Turato. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
U
Back to Top
M. Uddin. The selective BLT1 antagonist, CP-105696, used in the study was a gift from Dr M. Yeadon at Pfizer (Kent, UK). DOI: 10.1183/09031936.00144307
V
Back to Top
B.A. Vanaudenaerde. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
B.M. Vanaudenaerde is a senior research fellow of the FWO Vlaanderen – Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
L. Van Bortel. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
A. Van Muylem. AstraZeneca provided a grant for the exhaled biomarker laboratory. DOI: 10.1183/09031936.00020407
E. vanOort. The present study was supported by an unrestricted grant from AstraZeneca, Switzerland, and an unrestricted grant from Boehringer Ingelheim, Switzerland. DOI: 10.1183/09031936.00078707
D.E. Van Raemdonck. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
D.E. Van Raemdonck. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
C.P. van Schayck has received funding from Pfizer, Boehringer Ingehlheim and GSK. DOI: 10.1183/09031936.00074307
I. Van Tongelen. GlaxoSmithKline Belgium provided the peak flow meters for the author’s study. DOI: 10.1183/09031936.00112007
C. van Weel received the following unrestricted research and educational grants for the Dept of General Practice: less than US$10,000 from AstraZeneca, Bayer and NovoNordisk; and more than US$10,000 from Boehringer Ingelheim, GlaxoSmithKline and Novartis. The author has also received speaking fees. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
S. van Wijngaarden. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
A. Vatrella. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
E.K. Verbeken has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
G.M. Verleden. The author’s study was supported by AstraZeneca Belgium. DOI: 10.1183/09031936.00064807
G.M. Verleden. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
J. Verschakelen has received consulting fees from Zambon. The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual (IFIGENIA) study (additional study group members detailed in manuscript) was supported by the Zambon Group, Milan, Italy. DOI: 10.1183/09031936.00063706
J. Vestbo has received research grants to support work carried out in the department where he works from GlaxoSmithKline. He has received honoraria from GlaxoSmithKline, AstraZeneca, Boehringer-Ingeheim and Pfizer for speaking in scientific meetings and for travel to these meetings. J. Vestbo serves on an advisory board and expert panel for GlaxoSmithKline, AstraZeneca, Boehringer-Ingelheim and Hoffmann-La Roche. Finally, his wife is an employee of AstraZeneca. The author’s study was supported by GlaxoSmithKline. DOI: 10.1183/09031936.00111707
U. Vester. The author’s study was part of a project funded by Pharmacia. DOI: 10.1183/09031936.00103907
R. Vos is a research fellow of the FWO Vlaanderen – Research Foundation-Flanders. The work was supported by GlaxoSmithKline Belgium and Fonds voor Wetenschappelijk Onderzoek (FWO) Vlaanderen (G.0493.04, G.0518.06, G.0643.08). DOI: 10.1183/09031936.00128607
W
Back to Top
G.T.M. Wagenaar. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
F.J. Walther. The piclamilast used in the author’s study was a gift from Altana Pharma AG, Konstanz, Germany. DOI: 10.1183/09031936.00071307
J. Wattie. The author’s study was supported, in part, by a grant from GlaxoSmithKline (Canada). DOI: 10.1183/09031936.00079307
M. Weatherall. The author’s study was funded by GlaxoSmithKline, Stevenage, UK, who had no role in the design, data analysis or drafting of the manuscript. DOI: 10.1183/09031936.00065707
T. Welte received €4,000 in 2006 for speaking at conferences sponsored by BRAHMS AG. He also received €50,000 Euro in 2006 from BRAHMS AG as a research grant for participating in an investigator-initiated study. DOI: 10.1183/09031936.00054507
S.E. Wenzel has served on or currently serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Isis, GlaxoSmithKline, Genetech, Merck and Novartis, and has received honoraria for educational activities organised by AstraZeneca, Critical Therapeutics and Merck. The author’s institution has received funding for research from Amgen, Critical Therapeutics and Genetech. DOI: 10.1183/09031936.00138707
E. Wouters is a member of the scientific advisory boards for GSK, Boehringer Ingelheim, AstraZeneca and Numico, and has received lecture fees from GSK, AstraZeneca and Boehringer Ingelheim. Between 2004–2006, he received research grants from GSK, AstraZeneca, Boehringer Ingelheim, Centocor and Numico. The symposium upon which the author’s review article was based was made possible by an unrestricted educational grant from AstraZeneca Belgium (Brussels, Belgium). DOI: 10.1183/09031936.00066607
P. Wrighton-Smith is an employee of Oxford Immunotec, holds shares in Oxford Immunotec. P. Wrighton-Smith is an employee of, and shareholder in, Oxford Immunotec. DOI: 10.1183/09031936.00117207
W
Back to Top
Y
Back to Top
I.H. Young is employed by the Sydney South West Area Health Service (SSWAHS), the owner of the intellectual property of the use of mannitol for clearance of mucus, which has been licensed to Pharmaxis Ltd. The author would like to thank Pharmaxis Ltd for providing the mannitol for this study. The application for the use of mannitol described in this paper is covered by U.S. patent No. 5817028, Australian patent no. 682756, and International patent PCT/AU 95/00086. The patent is owned by the Sydney South West Area Health Service and has been licensed to Pharmaxis Ltd, Frenchs Forest, Australia, for development. DOI: 101183/09031936.00119707
T. Yue. The author’s study was supported by Abbott AG, Baar, Switzerland. DOI: 10.1183/09031936.00046307
Z
Back to Top
H.J. Zar has served on or currently serves on advisory boards for CiplaMedpro, Pfizer and Roche, and has received honoraria for educational activities organised by GlaxoSmithKline, Merck, Pfizer and Roche. The author’s institution has received funding for research from AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb, GlaxoSmithKline and Merck. DOI: 10.1183/09031936.00138707
J-P. Zellweger has been invited by Oxfordimmunotec in Oxford in 2004 and 2005 to attend workshops on Gamma-Interferon tests. DOI: 10.1183/09031936.00117207
R. Zuin. The present study was supported in part by an unrestricted grant from GlaxoSmithKline, Brentford, UK. DOI: 10.1183/09031936.00036707
Back to Top
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |